Replimune's innovative cancer therapies, strong cash reserves, and FDA support position it to disrupt oncology markets. Click ...

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that ...

Oncolytic viruses (OVs) are viruses that infect and kill cancer cells while sparing healthy tissue, making them a promising therapeutic option in cancer ...

Tax advantages offered by PEA-PME and PEA are only available to French residents. *Shares of European companies with fewer than 5,000 employees and an annual revenue of less than €1.5 billion or total ...

The Company’s clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the myvac® platform ...

The virus was a recombinant Newcastle disease virus with naturally oncolytic properties modified to include the porcine α1,3GT gene (NDV-GT). This virus commonly infects birds and causes only ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment. Oncolytic virus ...

The viruses used in virotherapy are called oncolytic viruses. An oncolytic virus kills a cancer cell by replicating inside cancer cells and breaking them open. The cancer-related antigens are then ...

This comprehensive whitepaper analyzes the evolving landscape of oncolytic virus therapies (OVT), providing critical insights into this transformative approach to cancer treatment.

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to ...